secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2023-03-31T23:59:59+00:00
Accession:  0001326110-23-000028
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio issues $30M convertible promissory note to Nant Capital, LLC
------------------------------------------------------------------------

- $30M principal, Term SOFR + 8% interest, due Dec 31, 2023.
- Investor is Nant Capital, LLC, affiliated with Executive Chairman Dr. Patrick Soon-Shiong.
- Net proceeds $29.85M after 0.5% origination fee; funds for pre-commercialization, R&D, and corporate purposes.
- Convertible at holder's option after next insider trading window opens at greater of Nasdaq closing or bid price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611023000028/0001326110-23-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611023000028/ibrx-20230331.htm
  HTML page:      https://secwatch.observer/filing/0001326110-23-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer